Neuroprotection abilities of cytosolic phospholipase A2 inhibitors in kainic acid-induced neurodegeneration

Current Drug Targets - Cardiovascular and Haematological Disorders

Volumn 4, Issue 1, 2004, Pages 85-96

  Farooqui, Akhlaq A ^a   Ong, Wei Yi ^b   Horrocks, Lloyd A ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; ALDEHYDE; ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ANTIMALARIAL AGENT; ARACHIDONIC ACID; ARACHIDONYL TRIFLUOROMETHYL KETONE; AUTACOID; BENZODIAZEPINE DERIVATIVE; CHLOROQUINE; CITRULLINE; FATTY ACID; GLUTAMATE RECEPTOR AGONIST; HYDROXYCHLOROQUINE; KAINIC ACID; KAINIC ACID RECEPTOR ANTAGONIST; LEUKOTRIENE; LYSOPHOSPHOLIPID; MEMBRANE PHOSPHOLIPID; MEPACRINE; N TERT BUTYL ALPHA PHENYLNITRONE; NEUROTRANSMITTER; PHOSPHOLIPASE A2 INHIBITOR; PROSTAGLANDIN; QUININE; SURFACTIN; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARIABILIN;

ARTERY WALL; ATHEROSCLEROTIC PLAQUE; BRAIN TISSUE; CALCIUM HOMEOSTASIS; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; CYTOSOL; DEGENERATIVE DISEASE; DISEASE COURSE; DRUG DISTRIBUTION; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; HIPPOCAMPUS; HUMAN; HYPOXIA; IC 50; INFLAMMATION; ISCHEMIA; LIPID HYDROLYSIS; METABOLITE; NERVE CELL LESION; NERVE FIBER GROWTH; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMITTER RELEASE; PATHOGENESIS; PROSTAGLANDIN SYNTHESIS; PROTEIN FAMILY; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BLOOD PROTEINS; CYTOSOL; HUMANS; KAINIC ACID; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PHOSPHOLIPASES A;

EID: 1642442420     PISSN: 15680061     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568006043481239     Document Type: Review

References (96)

1. Farooqui, A.A., Horrocks, L.A. Excitatory amino acid receptors, neural membrane phospholipid metabolism and neurological disorders. Brain Res. Rev., 1991, 16, 171-191.
2. Farooqui, A.A., Horrocks, L.A. Excitotoxicity and neurological disorders: Involvement of membrane phospholipids. Int. Rev. Neurobiol., 1994, 36, 267-323.
3. Monaghan, D.T., Bridges, R.J., Cotman, C.W. The excitatory amino acid receptors: Their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu. Rev. Pharmacol. Toxicol., 1989, 29, 365-402.
4. 2: Localization, role, and involvement in neurological diseases. Neuroscientist, 2000, 6, 169-180.
5. Farooqui, A.A., Horrocks, L.A., Farooqui, T. Deacylation and reacylation of neural membrane glycerophospholipids. J. Mol. Neurosci., 2000, 14, 123-135.
6. 2 inhibitors. Brain Res. Rev., 2001, 38, 61-78.
7. Sperk, G. Kainic acid seizures in the rat. Prog. Neurobiol., 1994, 42, 1-32.
8. 2 in neurodegeneration. Neurochem. Int., 1997, 30, 517-522.
9. 2 and its role in brain tissue. J. Neurochem., 1997, 69, 889-901.
10. 2s in cell injury and death. J. Pharmacol. Exp. Ther., 2000, 294, 793-799.
11. 2 in ischemic and toxic brain injury. Neurochem. Res., 2000, 25, 745-753.
12. 2 in atherosclerosis. Atherosclerosis 1997, 132, 1-8.
13. 2 - Possible implications for atherogenesis. Trends Cardiovasc. Med., 1999, 9, 232-238.
14. Libby, P. Molecular bases of the acute coronary syndromes. Circulation, 1995, 91, 2844-2850.
15. 2: Potential mediators of the systemic inflammatory response syndrome and the multiple organ dysfunction syndrome. Crit. Care Med., 1993, 21, 957-959.
16. Tomimoto, H., Akiguchi, I., Wakita, H., Kinoshita, A., Ikemoto, A., Nakamura, S., Kimura, J. Glial expression of cytokines in the brains of cerebrovascular disease patients. Acta Neuropathol. (Berl), 1996, 92, 281-287.
17. 2 in endothelium-derived hyperpolarizing factor dilations of rat middle cerebral arteries. J. Cereb. Blood Flow Metab., 2002, 22, 1239-1247.
18. 2: Basic and Clinical Aspects in Inflammatory Diseases; Karger: Basel, 1997.
19. Lerma, J., Paternain, A.V., Rodriguez-Moreno, A., Lopez-Garcia, J.C. Molecular physiology of kainate receptors. Physiol. Rev., 2001, 81, 971-998.
20. Lerma, J. Kainate reveals its targets. Neuron, 1997, 19, 1155-1158.
21. Ben-Ari, Y., Cossart, R. Kainate, a double agent that generates seizures: Two decades of progress. Trends Neurosci., 2000, 23, 580-587.
22. Mulle, C., Sailer, A., Swanson, G.T., Brana, C., O'Gorman, S., Bettler, B., Heinemann, S.F. Subunit composition of kainate receptors in hippocampal interneurons. Neuron, 2000, 28, 475-484.
23. Mulle, C., Sailer, A., Perez-Otano, I., Dickinson-Anson, H., Castillo, P.E., Bureau, I., Maron, C., Gage, F.H., Mann, J.R., Bettler, B., Heinemann, S.F. Altered synaptic physiology and reduced susceptibility to kainate-induced seizures in GluR6-deficient mice. Nature, 1998, 392, 601-605.
24. Chittajallu, R., Braithwaite, S.P., Clarke, V.R.J., Henley, J.M. Kainate receptors: Subunits, synaptic localization and function. Trends Pharmacol. Sci. 1999, 20, 26-35.
25. Michaelis, E.K. Molecular biology of glutamate receptors in the central nervous system and their role in excitotoxicity, oxidative stress and aging. Prog. Neurobiol., 1998, 54, 369-415.
26. Paternain, A.V., Herrera, M.T., Nieto, M.A., Lerma, J. GluR5 and GluR6 kainate receptor subunits coexist in hippocampal neurons and coassemble to form functional receptors. J. Neurosci., 2000, 20, 196-205.
27. Meldrum, B., Garthwaite, J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol. Sci., 1990, 11, 379-387.
28. Choi, D.W. Glutamate neurotoxicity and diseases of the nervous system. Neuron, 1988, 1, 628-634.
29. 2+ permeable AMPA or kainate receptors: Possible key factors in selective neurodegeneration. Trends Neurosci., 2000, 23, 365-371.
30. 2+ entry via AMPA/KA receptor and excitotoxicity in cultured cerebellar Purkinje cells. J. Neurosci., 1994, 14, 187-197.
31. Ong, W.Y., Ren, M.Q., Makjanic, J., Lim, T.M., Watt, F. A nuclear microscopic study of elemental changes in the rat hippocampus after kainate-induced neuronal injury. J. Neurochem., 1999, 72, 1574-1579.
32. 2 and cyclooxygenase-2 in the hippocampus after kainate lesions. Brain Res., 1998, 788, 223-231.
33. Ong, W.Y., He, Y., Suresh, S., Patel, S. Differential expression of apoD and apoE in the kainate lesioned rat hippocampus. Neuroscience, 1997, 79, 359-367.
34. Milatovic, D., Gupta, R.C., Dettbarn, W.D. Involvement of nitric oxide in kainic acid-induced excitotoxicity in rat brain. Brain Res., 2002, 957, 330-337.
35. Ong, W.Y., Goh, E.W., Lu, X.R., Farooqui, A.A., Patel, S.C., Halliwell, B. Increase in cholesterol and cholesterol oxidation products and role of cholesterol oxidation products in kainate-induced neuronal injury. Brain Pathol., 2003, 13, 250-262.
36. 2 and neuronal death after intracerebroventricular carrageenan injection and neuroprotective effects of quinacrine. Exp. Neurol., 2003, 183, 449-457.
37. Farooqui, A.A., Rammohan, K.W., Horrocks, L.A. Isolation, characterization and regulation of diacylglycerol lipases from bovine brain. Ann. N. Y. Acad. Sci., 1989, 559, 25-36.
38. Williams, J.H., Errington, M.L., Lynch, M.A., Bliss, T.V.P. Arachidonic acid induces a long-term activity dependent enhancement of synaptic transmission in the hippocampus. Nature, 1989, 341, 739-742.
39. 2 controls the induction of short-term versus long-term depression in the cerebellar Purkinje neuron in culture. Neuron, 1995, 15, 1393-1401.
40. Dumuis, A., Sebben, M., Haynes, L., Pin, J.-P., Bockaert, J. NMDA receptors activate the arachidonic acid cascade system in striatal neurons. Nature, 1988, 336, 68-70.
41. 2 and somatostatin release are activated in response to N-methyl-D-aspartate receptor stimulation in hypothalamic neurons in primary culture. J. Neuroendocrinol., 1991, 3, 515-522.
42. Lazarewicz, J.W., Salinska, E., Wroblewski, J.T. NMDA receptor-mediated arachidonic acid release in neurons: Role in signal transduction and pathological aspects. Adv. Exp. Med. Biol., 1992, 318, 73-89.
43. Birkle, D.L. Reciprocal regulation of fatty acid release in the brain by GABA and glutamate. Adv. Exp. Med. Biol., 1992, 318, 57-71.
44. Sanfeliu, C., Hunt, A., Patel, A.J. Exposure to N-methyl-D-aspartate increases release of arachidonic acid in primary cultures of rat hippocampal neurons and not in astrocytes. Brain Res., 1990, 526, 241-248.
45. 2 in brain cortical cultures. Biochem. J., 1995, 310, 83-90.
46. Schapira, A.H. Oxidative stress and mitochondrial dysfunction in neurodegeneration. Curr. Opin. Neurol., 1996, 9, 260-264.
47. Keyser, D.O., Alger, B.E. Arachidonic acid modulates hippocampal calcium current via protein kinase C and oxygen radicals. Neuron, 1990, 5, 545-553.
48. Farooqui, A.A., Rosenberger, T.A., Horrocks, L.A. Arachidonic acid, neurotrauma, and neurodegenerative diseases. In Handbook of Essential Fatty Acid Biology, Yehuda, S.; Mostofsky, D.I., Eds.; Humana Press: Totowa, NJ, 1997; Chapter 13, pp. 277-295.
49. Higuchi, Y., Yoshimoto, T. Arachidonic acid converts the glutathione depletion-induced apoptosis to necrosis by promoting lipid peroxidation and reducing caspase-3 activity in rat glioma cells. Arch. Biochem. Biophys., 2002, 400, 133-140.
50. Berlett, B.S., Stadtman, E.R. Protein oxidation in aging, disease, and oxidative stress. J. Biol. Chem., 1997, 272, 20313-20316.
51. Dean, R.T., Fu, S., Stocker, R., Davies, M.J. Biochemistry and pathology of radical-mediated protein oxidation. Biochem. J., 1997, 324, 1-18.
52. Choe, M., Jackson, C., Yu, B.P. Lipid peroxidation contributes to age-related membrane rigidity. Free Radical Biol. Med., 1995, 18, 977-984.
53. 2, and signal transduction. Brain Res. Rev., 1995, 21, 152-161.
54. Ray, P., Ray, R., Broomfield, C.A., Berman, J.D. Inhibition of bioenergetics alters intracellular calcium, membrane composition, and fluidity in a neuronal cell line. Neurochem. Res., 1994, 19, 57-63.
55. 2. Nature, 1997, 390, 622-625.
56. 2 are resistant to MPTP neurotoxicity. J. Neurochem., 1998, 71, 2634-2637.
57. Farooqui, A.A., Anderson, D.K., Horrocks, L.A. Effect of glutamate and its analogs on diacylglycerol and monoacylglycerol lipase activities of neuron-enriched cultures. Brain Res., 1993, 604, 180-184.
58. Farooqui, A.A., Ong, W.Y., Horrocks, L.A. Stimulation of lipases and phospholipases in Alzheimer disease. In Nutrition and Biochemistry of Phospholipids, Szuhaj, B.; van Nieuwenhuyzen, W., Eds.; AOCS Press: Champaign, 2003, Chapter 2, pp. 14-29.
59. Farooqui, A.A., Anderson, D.K., Horrocks, L.A. Glutamate and its analogs stimulate diacylglycerol and monoacylglycerol lipase activities in primary cultures enriched in neurons. J. Neurochem. 61, S10C. 1993.
60. Reid, C.A., Bliss, T.V. Learning about kainate receptors. Trends Pharmacol. Sci., 2000, 21, 159-160.
61. Esterbauer, H., Schaur, R.J., Zollner, H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med., 1991, 11, 81-128.
62. Uchida, K. 4-Hydroxy-2-nonenal: A product and mediator of oxidative stress. Prog. Lipid Res., 2003, 42, 318-343.
63. +-ATPase activity by oxygen free radicals. Neuro Report, 1995, 7, 333-337.
64. Friguet, B., Stadtman, E.R., Szweda, L.I. Modification of glucose-6-phosphate dehydrogenase by 4-hydroxy-2-nonenal. J. Biol. Chem., 1994, 269, 21639-21643.
65. Kooy, N., Royall, J., Ischoropoulos, H., Beckman, J. Peroxynitrite-mediated oxidation of dihydrorhodamine 123. Free Radic. Biol. Med., 1994, 16, 149-156.
66. Mertsch, K., Blasig, I., Grune, T. 4-Hydroxynonenal impairs the permeability of an in vitro rat blood-brain barrier. Neurosci. Lett., 2001, 314, 135-138.
67. Ciceri, P., Zhang, Y., Shaffer, A.F., Leahy, K.M., Woerner, M.B., Smith, W.G., Seibert, K., Isakson, P.C. Pharmacology of celecoxib in rat brain after kainate administration. J. Pharmacol. Exp. Ther., 2002, 302, 846-852.
68. Ong, W.Y., Hu, C.Y., Hjelle, O.P., Ottersen, O.P., Halliwell, B. Changes in glutathione in the hippocampus of rats injected with kainate: Depletion in neurons and upregulation in glia. Exp. Brain Res., 2000, 132, 510-516.
69. Farooqui, A.A., Horrocks, L. A., Farooqui, T. Glycerophospholipids in brain: Their metabolism, incorporation into membranes, functions, and involvement in neurological disorders. Chem. Phys. Lipids, 2000, 106, 1-29.
70. 2α as revealed by gene-targeted mice. Prostaglandins Other Lipid Mediat., 2002, 68-9, 59-69.
71. 2 knockout mouse: A new tool for physiology and cell biology. J. Am. Soc. Nephrol., 1999, 10, 404-412.
72. 2 activity: Their neurochemical effects and therapeutical importance for neurological disorders. Brain Res. Bull., 1999, 49, 139-153.
73. 2 inhibitors as therapeutic agents for neural cell injury. Curr. Med. Chem. - Anti-Inflammatory & Anti-Allergy Agents, 2002, 1, 193-204.
74. 2) and hydroxynonenal (HNE) in neurons of the lateral septum following fimbria-fornix transection. Exp. Brain Res., 2001, 138, 500-508.
75. 2 inhibitors on kainate-induced neuronal injury in rat hippocampal slices. Free Radical Biol. Med., 2001, 30, 1263-1273.
76. 2 inhibitor, quinacrine, reduces infarct size in rats after transient middle cerebral artery occlusion. Brain Res., 1997, 752, 203-208.
77. 2 mRNA levels in the rat hippocampus after kainate-induced neuronal injury. Exp. Brain Res., 2003, 148, 521-524.
78. Dubin, N.H., Blake, D.A., DiBlasi, M.C., Parmley, T.H., King, T.M. Pharmacokinetic studies on quinacrine following intrauterine administration to cynomolgus monkeys. Fert. Steril., 1982, 38, 735-740.
79. O'Regan, M.H., Smith-Barbour, M., Perkins, L.M., Phillis, J.W. A possible role for phospholipases in the release of neurotransmitter amino acids from ischemic rat cerebral cortex. Neurosci. Lett., 1995, 185, 191-194.
80. Crowe, R., Burnstock, G. Quinacrine-positive neurotics in some regions of the guinea-pig brain. Brain Res. Bull., 1984, 12, 387-391.
81. Blackwell, G.J.; Flower, R.J. Inhibition of phospholipase. Br. Med. Bull., 1983, 39, 260-264.
82. 2 in the hippocampus. Hippocampus, 1998, 8, 299-309.
83. 2. Eur. J. Pharmacol., 1999, 369, 373-386.
84. Korth, C., May, B.C., Cohen, F.E., Prusiner, S.B. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc. Natl. Acad. Sci. USA, 2001, 98, 9836-9841.
85. Farooqui, A.A., Taylor, W.A., Horrocks, L.A. Phospholipases, lysophospholipases and lipases and their involvement in various diseases. Neurochem. Pathol., 1987, 7, 99-128.
86. 2 is induced in reactive glia following different forms of neurodegeneration. Glia, 1999, 27, 110-128.
87. 2. Biochemistry, 1993, 32, 5935-5940.
88. 2. Biochemistry, 1993, 32, 12560-12565.
89. 2 by phosphorylation in rat mesangial cells. J. Clin. Invest., 1994, 93, 1224-1233.
90. 2-derived arachidonic acid and its metabolites. Brain Res., 1996, 721, 39-48.
91. 2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes. Arch. Toxicol., 1999, 73, 1-6.
92. 2. Biochem. Pharmacol., 1998, 55, 975-985.
93. 2. Eur. J. Pharmacol., 1997, 326, 237-250.
94. 2 by bromoenol lactone and trifluoromethyl ketones. J. Biol. Chem., 1995, 270, 445-450.
95. 2 by methyl arachidonyl fluorophosphonate. Biochim. Biophys. Acta Lipids Lipid Metab., 1996, 1302, 55-60.
96. 2, potentiates hydrogen peroxide cytotoxicity in kidney epithelial cells. J. Biol. Chem., 1996, 271, 21505-21513.